UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1283-8
Program Prior Authorization/Notification
Medication Vyndaqel® (tafamidis meglumine) and Vyndamax™ (tafamidis)
P&T Approval Date 6/2019, 2/2020, 2/2021, 2/2022, 2/2023, 9/2023, 9/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are transthyretin stabilizers indicated
for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated
amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related
hospitalization.
2. Coverage Criteriaa:
A. Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)
1. Initial Authorization
a. Vyndaqel/Vyndamax will be approved based on both of the following criteria:
(1) Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)
-AND-
(2) Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted
therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis),
Onpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Vyndaqel/Vyndamax will be approved based on both of the following criteria:
(1) Documentation that the patient has experienced a positive clinical response to
Vyndaqel/Vyndamax (e.g., improved symptoms, quality of life, slowing of disease
progression, decreased hospitalizations, etc.)
-AND-
(2) Patient is not receiving Vyndaqel/Vyndamax in combination with an RNA-targeted
therapy for ATTR amyloidosis [i.e., Amvuttra (vutrisiran), Attruby (acoramadis),
Onpattro (patisiran), Tegsedi (inotersen), or Wainua (eplontersen)]
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Medical Necessity may be in place
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Vyndaqel and Vyndamax [package insert]. Pfizer, Inc: New York, NY; October 2023.
2. Kittleson MM, Maurer MS, et al. American Heart Association Heart Failure and
Transplantation Committee of the Council on Clinical Cardiology. Cardiac
Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the
American Heart Association. Circulation. 2020 Jul 7;142(1):e7-e22.
3. Kittleson, M, Ruberg, F. et al. 2023 ACC Expert Consensus Decision Pathway on
Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A
Report of the American College of Cardiology Solution Set Oversight
Committee. JACC. 2023 Mar, 81 (11) 1076–1126.
Program Prior Authorization/Notification - Vyndaqel® (tafamidis meglumine) and
Vyndamax™ (tafamidis)
Change Control
6/2019 New program.
2/2020 Updated program to address potential combination amyloidosis treatment.
2/2021 Annual review with no change to coverage criteria. Updated reference.
2/2022 Annual review with no change to clinical criteria. Updated reference.
2/2023 Annual review with no change to coverage criteria. Added state mandate
footnote.
8/2023 Added reference to support requirement that Vyndamax/Vyndaqel are not
used in combination with another agent for cardiac amyloidosis.
9/2024 Annual review. Renamed and added examples of RNA-targeted therapies
for ATTR amyloidosis. Updated and added references.
1/2025 Updated criteria for monotherapy use. Added example of RNA-targeted
therapy for ATTR amyloidosis. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2